---
schema_version: "secwatch.filing_event.v1"
accession: "0001108205-24-000035"
form_type: "8-K"
ticker: "CRIS"
cik: "0001108205"
company_name: "CURIS INC"
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:17:05.323358+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Curis expands TakeAim Leukemia study to 30 patients; 6/11 FLT3m and 4/18 SFm respond

## Summary
- TakeAim Leukemia dataset expanded from 5 to 30 R/R AML patients (25 new) with emavusertib monotherapy at 300 mg BID.
- FLT3m cohort: 6/11 evaluable patients achieved objective response (3 CR, 1 CRh, 2 MLFS); responses mostly in one cycle.
- SFm cohort: 4/18 evaluable patients achieved objective response (1 CR, 2 CRh, 1 MLFS); 3 additional patients showed increased neutrophils.
- All responders had complete bone marrow blast normalization; two patients proceeded to allogenic stem cell transplant.
- Curis discloses insufficient cash to fund operations for next 12 months, highlighting need for additional capital.

## SEC filing metadata
- accession: 0001108205-24-000035
- form_type: 8-K
- ticker: CRIS
- cik: 0001108205
- company_name: CURIS INC
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1108205/000110820524000035/0001108205-24-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1108205/000110820524000035/cris-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001108205-24-000035
- JSON: https://secwatch.observer/filing/0001108205-24-000035.json
- Plain text: https://secwatch.observer/filing/0001108205-24-000035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.